+------------------------------------------------------------------------------+
Actelion Buy Repeated at Vontobel; Big Pharma May Be Interested 2014-02-12 07:59:42.465 GMT
By James Ludden Feb. 12 (Bloomberg) -- Opsumit progress prompts Vontobel to repeat buy rating, confirm peak sales forecast of CHF2.5b. * Actelion may attract interest again from “big pharma,” as co.’s long-term value is secured: Vontobel * Today: Actelion’s Opsumit May Face Study Comparing Gilead’s Letairis
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
--Editor: James Cone
To contact the reporter on this story: James Ludden in London at +44-20-7673-2645 or jludden@bloomberg.net
To contact the editor responsible for this story: Andrew Rummer at +44-20-7073-3722 or arummer@bloomberg.net